See more : Aluminum Corporation of China Limited (ACH) Income Statement Analysis – Financial Results
Complete financial analysis of CBD Life Sciences Inc. (CBDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CBD Life Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Land Securities Group plc (LSGOF) Income Statement Analysis – Financial Results
- Nippon Hume Corporation (5262.T) Income Statement Analysis – Financial Results
- KPIT Technologies Limited (KPITTECH.NS) Income Statement Analysis – Financial Results
- DAIHEN Corporation (6622.T) Income Statement Analysis – Financial Results
- Daimler Truck Holding AG (DTG.DE) Income Statement Analysis – Financial Results
CBD Life Sciences Inc. (CBDL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://lbcbioscienceinc.com
About CBD Life Sciences Inc.
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.15K | 160.24K | 59.26K | 225.90K | 79.64K | 122.79K | 155.55K | 0.00 | 0.00 |
| Cost of Revenue | 197.75K | 440.50K | 207.51K | 438.13K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.60K | -280.26K | -148.25K | -212.23K | 36.63K | 122.79K | 155.55K | 0.00 | 0.00 |
| Gross Profit Ratio | -18.31% | -174.90% | -250.18% | -93.95% | 46.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.20K | 0.00 | 1.39K | 314.85 | 337.43 | 752.49K | 442.90K | 53.29K | 44.12K |
| Selling & Marketing | 11.34K | 0.00 | 4.41K | 30.00 | 111.54 | 108.00K | 17.48K | 6.46K | 8.02K |
| SG&A | 46.05K | 571.77K | 4.96M | 171.86K | 906.25K | 860.49K | 460.38K | 59.75K | 52.14K |
| Other Expenses | 0.00 | -7.78K | -17.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 47.97K | 579.55K | 4.98M | 171.86K | 906.25K | 883.80K | 499.04K | 155.72K | 52.74K |
| Cost & Expenses | 245.72K | 1.02M | 5.19M | 609.99K | 949.26K | 883.80K | 499.04K | 155.72K | 52.74K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 69.91K | 0.00 | 15.27K | 23.50K | 0.00 | 0.00 |
| Depreciation & Amortization | 55.56K | 53.56K | 236.56K | 206.30K | 171.86K | 23.31K | 38.66K | 95.97K | 0.00 |
| EBITDA | -23.02K | -806.25K | -5.13M | -1.31M | -869.62K | -741.56K | -304.97K | -60.36K | -52.74K |
| EBITDA Ratio | -13.77% | -503.14% | -8,654.23% | -170.03% | -1,092.01% | -600.79% | -195.96% | 0.00% | 0.00% |
| Operating Income | -78.57K | -859.80K | -5.13M | -384.09K | -869.62K | -780.14K | -367.14K | -156.33K | -52.74K |
| Operating Income Ratio | -47.01% | -536.57% | -8,654.23% | -170.03% | -1,092.01% | -635.35% | -236.02% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00 | -2.00 | -1.31M | 8.61K | -15.27K | -23.50K | 0.00 | 0.00 |
| Income Before Tax | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Income Before Tax Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 | -6.14K | -384.09 | -75.24 | 15.27K | 23.50K | 610.00 | 0.00 |
| Net Income | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Net Income Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| Weighted Avg Shares Out | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
| Weighted Avg Shares Out (Dil) | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
CBD Life Sciences, Inc. (CBDL) Expands Product Line with NEW 3000MG Pain Relief Cream for its Online Store & Amazon
SCOTTSDALE, AZ / ACCESSWIRE / June 30, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the company is yet again expanding its product line with all new pain relief cream....
CBD Life Sciences, Inc. (CBDL) Launches 2nd Retail Location
SCOTTSDALE, AZ / ACCESSWIRE / June 15, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. announces that the Grand Opening of their 2nd retail location that took place this past weekend on...
CBD Life Sciences, Inc. (CBDL) Appoints Matthew McGee as Chief Marketing Officer
SCOTTSDALE, AZ / ACCESSWIRE / June 3, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. is proud to announce that they have appointed Matthew McGee to serve as Chief Marketing Officer of...
CBD Life Sciences, Inc. (CBDL) Announces Retail Store Updates
SCOTTSDALE, AZ / ACCESSWIRE / May 19, 2021 / Today, CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson is proud to provide the shareholders with retail store updates. CBD Life...
CBD Life Sciences, Inc. (CBDL) Launches Top Selling Pain Cream & Gummies on its Amazon Store
SCOTTSDALE, AZ / ACCESSWIRE / May 17, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson announced the launch of two new products on its Amazon Store Located...
CBD Life Sciences, Inc. (CBDL) Announces the Official Grand Opening of its Amazon Store
SCOTTSDALE, AZ / ACCESSWIRE / May 6, 2021 / Today, CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson announced the official grand opening of its Amazon Store Located at www.amazon.com/shops/lbcbioscienceinc....
CBD Life Sciences, Inc. (CBDL) Issues Strategic Corporate Overview.
SCOTTSDALE, AZ / ACCESSWIRE / April 14, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson has issued this strategic overview for its shareholders highlighting the following news...
CBD Life Sciences, Inc. (CBDL) Expands Product Line with NEW Delta-10 Cartridges
SCOTTSDALE, AZ / ACCESSWIRE / March 31, 2021 / Today CBD Life Sciences (OTC PINK:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson announces its all new Delta-10 Cartridges. CBD Life Sciences Inc. is working...
CBD Life Sciences, Inc. (CBDL) Engages EVIO Labs to Provide Product Certification Testing of CBDL Products
SCOTTSDALE, AZ / ACCESSWIRE / March 17, 2021 / CBD Life Sciences, Inc. (OTC PINK:CBDL) ("CBD Life Science" or the "Company"), a manufacturer and distributor of organic cannabidiol based products, announces today its commitment to providing products with the highest...
CBD Life Sciences Inc. (CBDL) enters the Kosher Market
SCOTTSDALE, AZ / ACCESSWIRE / March 4, 2021 / Today CBD Life Sciences (OTC PINK:CBDL), through its wholly-owned subsidiary, LBC Bioscience Inc. President & CEO, Lisa Nelson, announces that the company is entering the Kosher Market. CBD Life Sciences Inc....
Source: https://incomestatements.info
Category: Stock Reports